Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carl Zeiss Meditec AGXSWX:AFX 73 3-Year Share Buyback Ratio is 0.70 as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 73/100 and a GF Value™ of CHF71.28 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 615 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks better than 89.59% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Carl Zeiss Meditec AG's current 3-Year Share Buyback Ratio was 0.70%.
The historical rank and industry rank for Carl Zeiss Meditec AG's 3-Year Share Buyback Ratio or its related term are showing as below:
XSWX:AFX'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -35.7 Med: 0 Max: 0.7
Current: 0.7
During the past 13 years, Carl Zeiss Meditec AG's highest 3-Year Share Buyback Ratio was 0.70%. The lowest was -35.70%. And the median was 0.00%.
XSWX:AFX's 3-Year Share Buyback Ratio is ranked better than 89.59% of 615
companies
in the Medical Devices & Instruments industry
Industry Median: -2.7
vs XSWX:AFX: 0.70
Carl Zeiss Meditec AG (XSWX:AFX) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Carl Zeiss Meditec AG 3-Year Share Buyback Ratio Related Terms
XSWX:AFX vs ISRG, BDX, MDLN: 3-Year Share Buyback Ratio Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's 3-Year Share Buyback Ratio falls into.
Carl Zeiss Meditec AG 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 0.70 mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a 3-Year Share Buyback Ratio of 0.70 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Carl Zeiss Meditec AG and its competitors. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #64 out of 615 companies in the Medical Devices & Instruments industry, placing it in the top 10.4%.
Is Carl Zeiss Meditec AG's 3-Year Share Buyback Ratio too high?
Carl Zeiss Meditec AG's current 3-Year Share Buyback Ratio is 0.70. Based on the distribution chart, Carl Zeiss Meditec AG ranks #64 out of 615 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Carl Zeiss Meditec AG has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's 3-Year Share Buyback Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #64 out of 615 companies for 3-Year Share Buyback Ratio. This places Carl Zeiss Meditec AG in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current 3-Year Share Buyback Ratio is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF71.28, compared to a current price of CHF27.02 — trading 62.1% below its estimated fair value. The current 3-Year Share Buyback Ratio is 0.70. Carl Zeiss Meditec AG's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current 3-Year Share Buyback Ratio is 0.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF27.02 is trading 62.1% below its estimated GF Value™ of CHF71.28.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for XSWX:AFX:
3-Year Share Buyback Ratio: 0.70
GF Value™: CHF71.28 vs. price of CHF27.02 (62.1% below fair value)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
73GF Score
Get the complete analysis for XSWX:AFX
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
